FDA Flags Novo’s Wegovy Pill Ad as Misleading FDA says Novo Nordisk’s TV ad contains false or misleading claims Agency warns ad implies superiority over other GLP-1 drugs FDA letter demands immediate corrective action Claims like “live lighter” and “a way forward” singled out Risk disclosures reportedly failed compliance standards Comes as Novo fights […]
FDA Flags Novo’s Wegovy Pill Ad as Misleading Read More »
Novo vs. Hims: Weight-Loss Drug Battle Sends Shockwaves Through Health Market (Overview) Novo Nordisk files lawsuit against Hims & Hers over Wegovy copycats Court ban requested on compounded versions of semaglutide drugs FDA signals crackdown on mass-marketed GLP-1 compounds Hims pulls its new obesity pill after regulatory pressure Hims stock plunges up to 27% in
Novo Nordisk Sues Hims & Hers Over Wegovy Copycats; HIMS Stock Falls Read More »
US Patient Engagement Solutions Market — Quick Snapshot Market expected to grow from $14.55B (2025) to $25.01B (2030) Strong 11.4% CAGR driven by digital health adoption Growth powered by telehealth, remote monitoring, and AI-driven engagement Value-based care and chronic disease management are major drivers Smartphones and patient portals are reshaping patient interaction Oracle and McKesson
US Patient Engagement Solutions Market Growth & Leaders 2030 Read More »
